Previous 10 | Next 10 |
MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...
ODD Follows RMAT Designation Granted to ALLO-715 by the U.S. Food and Drug Administration in Multiple Myeloma Patients Phase 1 Data from the ALLO-715 UNIVERSAL Trial Demonstrated for the First Time that an Allogeneic CAR T Therapy Directed at BCMA Can Achieve Clinical Responses While ...
Allogene Therapeutics, Inc. (ALLO) Q2 2021 Earnings Conference Call August 04, 2021, 05:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and CEO Rafael Amado - EVP, Research and Development and CMO Eric Schmidt - CFO Conference Call Parti...
Allogene Therapeutics (NASDAQ:ALLO): Q2 GAAP EPS of -$0.53 beats by $0.02. Revenue of $0.04M. The Company had $913.2M in cash, cash equivalents, and investments as of June 30, 2021. Allogene continues to expect FY GAAP Operating Expenses to be between $300 and $330M including estima...
CD19 Program Highlights Phase 1 ALPHA Data at ASCO 2021 Showed a Single Dose of ALLO-501 was Associated with Overall Response, Complete Response and Durable Response Rates on Par with Autologous CD19 CAR T Therapies in CAR T Naïve Patients with Relapsed/Refractory Non-Hodgk...
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Elizabeth (Liz) Barre...
SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report second quarter 2021 ...
ALLO is one of the front runners in the development of allogeneic CAR T cell therapies, with an exciting pipeline of candidates. The share price is currently expensive and appears to ignore risks that clinical trials may not be successful. Valuation should be revisited in the futu...
Gainers: [[ASPU]] +6.9%. [[SDC]] +4.9%. [[XM]] +4.5%. [[AFIB]] +4.3%. [[NERV]] +4.0%.Losers: [[SNBR]] -10.2%. [[LUMO]] -9.3%. [[KRUS]] -8.3%. [[ALLO]] -5.0%. [[SYBX]] -4.8%. For further details see: ASPU, AFIB, SNBR and LUMO among after-hours movers
Phase I trials mean more usual for Cellectis. Cellectis is pursuing low-hanging fruit indications. New pipeline programs and their IP position offer upside on top of their CAR-T programs. For further details see: Cellectis Offers An Idiosyncratic Risk Profile With Remark...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger ® Technology to Optimize CAR T Cell Expansion and Pe...
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology compan...